LeMaitre Vascular is an American medical device company established in 1986 by vascular surgeon George D. LeMaitre, and based in Burlington, Massachusetts, which provides devices, implants and human tissue cryopreservation services used by surgeons in the treatment of vascular conditions, particularly peripheral vascular disease. As of 2022, LeMaitre Vascular sells directly to hospitals in 25 countries and through distributors in more than 70 countries throughout North America, Europe and Asia/Pacific Rim.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LMAT | LEMAITRE VASCULAR INC | 2026-03-03 12:05:19 | 104.11 | -3.28 | -3.06 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LMAT | 0001158895 | LEMAITRE VASCULAR INC | US5255582018 | 549300FZUBUB7MHY8R17 | — | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | — | 63 SECOND AVENUE | BURLINGTON | MA | 01803 | UNITED STATES | US | 781-221-2266 | 63 SECOND AVENUE, BURLINGTON, MA, 01803 | 63 SECOND AVENUE, BURLINGTON, MA, 01803 | — | Medical device | 1986-01-15 | — | 651 | https://www.lemaitre.com/ | 1,700,000,000 | 24,396,904 | 22,778,363 | LeMaitre Vascular is an American medical device company established in 1986 by vascular surgeon George D. LeMaitre, and based in Burlington, Massachusetts, which provides devices, implants and human tissue cryopreservation services used by surgeons in the treatment of vascular conditions, particularly peripheral vascular disease. As of 2022, LeMaitre Vascular sells directly to hospitals in 25 countries and through distributors in more than 70 countries throughout North America, Europe and Asia/Pacific Rim. | 2026-02-26 17:23:42 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,700,000,000 | 0 | 0 | 22,778,363 | 219,732 | 0.974 |
| 2024 | 1,700,000,000 | 400,000,000 | 30.7692 | 22,558,631 | 221,415 | 0.9912 |
| 2023 | 1,300,000,000 | 420,880,900 | 47.8753 | 22,337,216 | 239,912 | 1.0857 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| David B. Roberts | President | 2024 | 406,762 | 15,000 | 270,000 | 176,053 | 10,350 | 1,148,165 |
| Trent G. Kamke | Senior Vice President | 2024 | 316,554 | 17,000 | 187,500 | 150,800 | 10,350 | 859,354 |
| George W. Lemaitre | Chairman, Chief Executive Officer | 2024 | 622,292 | 0 | 1,000,000 | 527,958 | 85,308 | 3,235,558 |
| Joseph P. Pellegrino | Chief Financial Officer | 2024 | 419,862 | 0 | 337,500 | 216,683 | 0 | 1,311,545 |
| Trent G. Kamke | Senior Vice President | 2023 | 301,480 | 13,250 | 112,500 | 120,750 | 9,900 | 668,380 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 655 |
| 2024 | 664 |
| 2023 | 630 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 249,602,000 | 219,863,000 | 193,484,000 |
| Cost Of Revenue | 71,063,000 | 68,962,000 | 66,435,000 |
| Gross Profit | 178,539,000 | 150,901,000 | 127,049,000 |
| Research And Development Expenses | 14,139,000 | 15,650,000 | 16,966,000 |
| General And Administrative Expenses | 42,024,000 | 36,258,000 | 31,832,000 |
| Operating Expenses | 110,627,000 | 98,645,000 | 90,337,000 |
| Operating Income | 67,912,000 | 52,256,000 | 36,712,000 |
| Net Income | 57,734,000 | 44,038,000 | 30,105,000 |
| Earnings Per Share Basic | 2.55 | 1.96 | 1.36 |
| Earnings Per Share Diluted | 2.52 | 1.93 | 1.34 |
| Weighted Average Shares Outstanding Basic | 22,638,000 | 22,452,000 | 22,217,000 |
| Weighted Average Shares Outstanding Diluted | 22,929,000 | 22,779,000 | 22,423,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 28,244,000 | 25,610,000 | 24,269,000 |
| Marketable Securities Current | 330,876,000 | 274,112,000 | 80,805,000 |
| Accounts Receivable | 33,610,000 | 30,063,000 | 25,064,000 |
| Inventories | 70,422,000 | 64,927,000 | 58,080,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 468,232,000 | 402,192,000 | 194,598,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 26,997,000 | 24,800,000 | 21,754,000 |
| Other Assets Non Current | 4,906,000 | 4,868,000 | 3,740,000 |
| Total Assets Non Current | 42,759,000 | 41,568,000 | 39,781,000 |
| Total Assets | 615,690,000 | 551,817,000 | 346,778,000 |
| Accounts Payable | 3,646,000 | 1,761,000 | 3,734,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 0 | 0 | — |
| Other Liabilities Current | 29,411,000 | 24,732,000 | 23,650,000 |
| Total Liabilities Current | 36,323,000 | 30,607,000 | 29,879,000 |
| Long Term Debt | 168,645,000 | 167,772,000 | — |
| Other Liabilities Non Current | 1,468,000 | 831,000 | 2,268,000 |
| Total Liabilities Non Current | 185,851,000 | 183,920,000 | 18,999,000 |
| Total Liabilities | 222,174,000 | 214,527,000 | 48,878,000 |
| Common Stock | 244,000 | 242,000 | 239,000 |
| Retained Earnings | 184,715,000 | 145,090,000 | 115,430,000 |
| Accumulated Other Comprehensive Income | -2,411,000 | -6,184,000 | -4,625,000 |
| Total Shareholders Equity | 393,516,000 | 337,290,000 | 297,900,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 10,418,000 | 9,670,000 | 9,515,000 |
| Share Based Compensation Expense | 7,826,000 | 6,568,000 | 5,319,000 |
| Other Non Cash Income Expense | — | 0 | 0 |
| Change In Accounts Receivable | 2,947,000 | 6,418,000 | 3,135,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 81,251,000 | 44,124,000 | 36,751,000 |
| Purchases Of Marketable Securities | 641,329,000 | 277,938,000 | 16,551,000 |
| Sales Of Marketable Securities | 585,070,000 | 84,780,000 | 0 |
| Acquisition Of Property Plant And Equipment | 6,783,000 | 6,962,000 | 7,265,000 |
| Acquisition Of Business | 1,899,000 | 0 | 899,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -64,941,000 | -200,120,000 | -24,715,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 18,109,000 | 14,378,000 | 12,448,000 |
| Issuance Of Common Stock | — | 6,440,000 | 6,170,000 |
| Repurchase Of Common Stock | 1,821,000 | 1,719,000 | 853,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -14,540,000 | 158,102,000 | -7,131,000 |
| Change In Cash | 2,634,000 | 1,341,000 | 5,135,000 |
| Cash At End Of Period | 28,244,000 | 25,610,000 | 24,269,000 |
| Income Taxes Paid | 13,439,000 | 12,837,000 | 7,549,000 |
| Interest Paid | 5,184,000 | 205,000 | 0 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 2.55 | 1.96 | 1.36 |
| Price To Earnings Ratio | 31.8039 | 47.0102 | 41.7353 |
| Earnings Growth Rate | 30.102 | 44.1176 | 44.6809 |
| Price Earnings To Growth Ratio | 1.0565 | 1.0656 | 0.9341 |
| Book Value Per Share | 17.383 | 15.0227 | 13.4087 |
| Price To Book Ratio | 4.6655 | 6.1334 | 4.2331 |
| Ebitda | 86,775,000 | 66,750,000 | 47,169,000 |
| Enterprise Value | 1,976,342,800 | 2,210,889,280 | — |
| Dividend Yield | 0.0099 | 0.007 | 0.0099 |
| Dividend Payout Ratio | 0.3137 | 0.3265 | 0.4135 |
| Debt To Equity Ratio | 0.4286 | 0.4974 | — |
| Capital Expenditures | 12,615,000 | 12,716,000 | 13,368,000 |
| Free Cash Flow | 68,636,000 | 31,408,000 | 23,383,000 |
| Return On Equity | 0.1467 | 0.1306 | 0.1011 |
| One Year Beta | 0.6708 | 1.013 | 0.6545 |
| Three Year Beta | 0.7421 | 0.8285 | 0.8003 |
| Five Year Beta | 0.7891 | 0.972 | 0.9719 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| LeMaitre George W | Director, Chairman and CEO | 2026-03-02 | 5,000 | D | 1,532,430 |
| LeMaitre George W | Director, Chairman and CEO | 2026-03-02 | 55,930 | D | 1,476,500 |
| Roberts David B | Director, President and Director | 2026-02-27 | 8,464 | D | 17,979 |
| Kamke Trent G | Senior V. P., Operations | 2026-02-27 | 1,044 | D | 6,677 |
| Pellegrino Joseph P JR | Director | 2026-02-26 | 1,893 | A | 12,076 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 14,760 | 182 | 81.0989 |
| Bell Investment Advisors, Inc | 2025-12-31 | 487 | 6 | 81.1667 |
| Pacer Advisors, Inc. | 2025-12-31 | 120,920 | 1,491 | 81.0999 |
| Invesco Ltd. | 2025-12-31 | 9,377,674 | 115,631 | 81.1 |
| NewEdge Advisors, LLC | 2025-12-31 | 256,114 | 3,158 | 81.1001 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| JAMES ADVANTAGE FUNDS | 2025-12-31 | JAMES MICRO CAP FUND | JMCRX | 2,165 | 175,581.5 | 0.6502 |
| Lazard Active ETF Trust | 2025-12-31 | Lazard US Systematic Small Cap Equity ETF | SYZ | 2,618 | 212,319.8 | 0.384 |
| LAZARD FUNDS INC | 2025-12-31 | Open Shares | LEOOX | 42,383 | 3,942.33 | 0.0065 |
| LAZARD FUNDS INC | 2025-12-31 | Institutional Shares | LEOIX | 42,383 | 3,942.33 | 0.0065 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 29 | 2,351.9 | 0.0279 |